MALT lymphoma

Changed by Mohammad Taghi Niknejad, 23 Dec 2023
Disclosures - updated 12 Nov 2023: Nothing to disclose

Updates to Article Attributes

Body was changed:

Mucosa-associated lymphoid tissue (MALT) lymphoma, sometimes shortened to MALToma, is a type of low-grade extranodal lymphoma.

Terminology

In the 5th edition of the WHO classification of haematolymphoid tumours, it is a mature B-cell neoplasm termed extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. This is a separate entity from "nodal marginal zone lymphoma", fundfound in the marginal zone of the germinal follicles of a lymph node.

Epidemiology

MALT lymphoma represents ~7.5% of non-Hodgkin lymphomas. The average age of presentation is 60 years with a slight female predominance 1. Prevalence is estimated at 2 per 100,000 7

Clinical presentation

Clinical presentation depends on the affected organ. B-type symptoms are rare 1,3.

Pathology

MALT lymphomas arise in epithelial tissues where lymphoid cells are not usually found. Chronic infection/inflammation has been implicated in the pathogenesis, for example, Helicobacter pylori infection with gastric MALT lymphoma, and Sjögren syndrome with salivary gland MALT lymphoma 1,3. Less than 10% transform from low-grade to high-grade disease 4.

MALT lymphoma can localise throughout the entire body 1,4:

Metastases to other sites including lymph nodes and bone marrow are not uncommon. 

Radiographic features

Imaging features of MALT lymphoma depend on which organ is affected. 

Treatment and prognosis

MALT lymphoma is considered an indolent disease with a good prognosis. Treatment should be tailored to the affected organ and may consist of surgery, chemotherapy, and/or radiation therapy 2. Antibiotics are used to treat gastric MALT lymphoma; there is a lack of evidence for their use in treating non-gastric MALT lymphoma 7.

See also

  • -<p><strong>Mucosa-associated lymphoid tissue (MALT)</strong> <strong>lymphoma</strong>, sometimes shortened to <strong>MALToma</strong>,&nbsp;is a type of low-grade extranodal <a href="/articles/lymphoma">lymphoma</a>.</p><h4>Terminology</h4><p>In the 5<sup>th</sup> edition of the <a href="/articles/who-classification-of-haematolymphoid-tumours" title="WHO classification of haematolymphoid tumours">WHO classification of haematolymphoid tumours</a>, it is a mature B-cell neoplasm termed <strong>extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue</strong>. This is a separate entity from "nodal <a href="/articles/marginal-zone-lymphoma" title="Marginal zone lymphoma">marginal zone lymphoma</a>", fund in the marginal zone of the germinal follicles of a lymph node.</p><h4>Epidemiology</h4><p>MALT lymphoma represents ~7.5% of <a href="/articles/non-hodgkin-lymphoma">non-Hodgkin lymphomas</a>. The average age of presentation is 60 years with a slight female predominance <sup>1</sup>. Prevalence is estimated at 2 per 100,000 <sup>7</sup>.&nbsp;</p><h4>Clinical presentation</h4><p>Clinical presentation depends on the affected organ. <a href="/articles/b-symptoms">B-type symptoms</a> are rare <sup>1,3</sup>.</p><h4>Pathology</h4><p>MALT lymphomas arise in epithelial tissues where lymphoid cells are not usually found. Chronic infection/inflammation has been implicated in the pathogenesis, for example, <em>Helicobacter pylori</em> infection with <a href="/articles/gastric-malt-lymphoma">gastric MALT lymphoma</a>,&nbsp;and <a href="/articles/sjogren-syndrome-1">Sjögren syndrome</a> with <a href="/articles/salivary-gland">salivary gland</a> MALT lymphoma <sup>1,3</sup>. Less than 10% transform from low-grade to high-grade disease <sup>4</sup>.</p><p>MALT lymphoma can localise throughout the entire body <sup>1,4</sup>:</p><ul>
  • +<p><strong>Mucosa-associated lymphoid tissue (MALT)</strong> <strong>lymphoma</strong>, sometimes shortened to <strong>MALToma</strong>,&nbsp;is a type of low-grade extranodal <a href="/articles/lymphoma">lymphoma</a>.</p><h4>Terminology</h4><p>In the 5<sup>th</sup> edition of the <a href="/articles/who-classification-of-haematolymphoid-tumours" title="WHO classification of haematolymphoid tumours">WHO classification of haematolymphoid tumours</a>, it is a mature B-cell neoplasm termed <strong>extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue</strong>. This is a separate entity from "nodal <a href="/articles/marginal-zone-lymphoma" title="Marginal zone lymphoma">marginal zone lymphoma</a>", found in the marginal zone of the germinal follicles of a lymph node.</p><h4>Epidemiology</h4><p>MALT lymphoma represents ~7.5% of <a href="/articles/non-hodgkin-lymphoma">non-Hodgkin lymphomas</a>. The average age of presentation is 60 years with a slight female predominance <sup>1</sup>. Prevalence is estimated at 2 per 100,000 <sup>7</sup>.&nbsp;</p><h4>Clinical presentation</h4><p>Clinical presentation depends on the affected organ. <a href="/articles/b-symptoms">B-type symptoms</a> are rare <sup>1,3</sup>.</p><h4>Pathology</h4><p>MALT lymphomas arise in epithelial tissues where lymphoid cells are not usually found. Chronic infection/inflammation has been implicated in the pathogenesis, for example, <em>Helicobacter pylori</em> infection with <a href="/articles/gastric-malt-lymphoma">gastric MALT lymphoma</a>,&nbsp;and <a href="/articles/sjogren-syndrome-1">Sjögren syndrome</a> with <a href="/articles/salivary-gland">salivary gland</a> MALT lymphoma <sup>1,3</sup>. Less than 10% transform from low-grade to high-grade disease <sup>4</sup>.</p><p>MALT lymphoma can localise throughout the entire body <sup>1,4</sup>:</p><ul>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.